Table 1.
Individual patient characteristics
| Patient | Stadium | Tumour histology | Age | T | N | M | Gleason score/grade* | Surgery | PSA |
|---|---|---|---|---|---|---|---|---|---|
| Prostate cancer | |||||||||
| P1 | II | Adenocarcinoma | 52 | 2c | 0 | 0 | 3+4 | Operable | 3.3 ng/mL; 16.5% |
| P2 | II | Adenocarcinoma | 64 | 2c | 0 | 0 | 3+3 | Operable | 2.78 ng/mL; 12% |
| P3 | II | Adenocarcinoma | 55 | 2c | 0 | 0 | 4+4 | Operable | 8.2 ng/mL; 8.5% |
| Urinary bladder cancer | |||||||||
| B1 | 0a | Papillary carcinoma | 64 | a | 0 | 0 | 2 | Operable | n/a |
| B2 | I | Papillary carcinoma | 73 | 1 | 0 | 0 | 2 | Operable | n/a |
| B3 | 0a | Papillary carcinoma | 76 | a | 0 | 0 | 2 | Operable | n/a |
| Kidney cancer | |||||||||
| K1 | III | Clarocellulare carinoma | 66 | 3a | 0 | 0 | 3 | Operable | n/a |
| K2 | II | Clarocellulare carinoma | 70 | 2 | 0 | 0 | 2 | Operable | n/a |
*
Gleason score for prostate cancer; grade for Urinary bladder cancer and kidney cancer. PSA: prostate-specific antigen; n/a: not applicable.